Sökning: L773:0006 3002 OR L773:0304 4165 OR L773:1872 8006 >
Ebselen and analogs...
Ebselen and analogs as inhibitors of Bacillus anthracis thioredoxin reductase and bactericidal antibacterials targeting Bacillus species, Staphylococcus aureus and Mycobacterium tuberculosis
-
- Gustafsson, Tomas N. (författare)
- Umeå universitet,Klinisk bakteriologi,Karolinska Inst, Div Biochem, Dept Med Biochem & Biophys, Scheeles Vag 2, SE-17177 Stockholm, Sweden.; Umea Univ, Sunderby Res Unit, Dept Clin Microbiol, Clin Bacteriol, Umea, Sweden
-
- Osman, Harer (författare)
- Karolinska Inst, Div Biochem, Dept Med Biochem & Biophys, Scheeles Vag 2, SE-17177 Stockholm, Sweden
-
- Werngren, Jim (författare)
- Publ Hlth Agcy Sweden, Dept Microbiol, Solna, Sweden
-
visa fler...
-
- Hoffner, Sven (författare)
- Karolinska Institutet
-
- Engman, Lars (författare)
- Uppsala universitet,Syntetisk organisk kemi
-
- Holmgren, Arne (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2016
- 2016
- Engelska.
-
Ingår i: Biochimica et Biophysica Acta - General Subjects. - : Elsevier BV. - 0304-4165 .- 1872-8006 .- 0006-3002. ; 1860:6, s. 1265-1271
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Bacillus anthracis is the causative agent of anthrax, a disease associated with a very high mortality rate in its invasive forms. Methods: We studied a number of ebselen analogs as inhibitors of B. anthracis thioredoxin reductase and their antibacterial activity on Bacillus subtilis, Staphylococcus aureus, Bacillus cereus and Mycobacterium tuberculosis. Results: The most potent compounds in the series gave IC50 values down to 70 nM for the pure enzyme and minimal inhibitory concentrations (MICs) down to 0.4 mu M (0.12 mu g/ml) for B. subtilis,1.5 mu M (0.64 mu g/ml) for S. aureus, 2 mu M (0.86 mu g/ml) for B. cereus and 10 mu g/ml for M. tuberculosis. Minimal bactericidal concentrations (MBCs) were found at 1-1.5 times the MIC, indicating a general, class-dependent, bactericidal mode of action. The combined bacteriological and enzymological data were used to construct a preliminary structure-activity-relationship for the benzoisoselenazol class of compounds. When S. aureus and B. subtilis were exposed to ebselen, we were unable to isolate resistant mutants on both solid and in liquid medium suggesting a high resistance barrier. Conclusions: These results suggest that ebselen and analogs thereof could be developed into a novel antibiotic class, useful for the treatment of infections caused by B. anthracis, S. aureus, M. tuberculosis and other clinically important bacteria. Furthermore, the high barrier against resistance development is encouraging for further drug development. General significance: We have characterized the thioredoxin system from B. anthracis as a novel drug target and ebselen and analogs thereof as a potential new class of antibiotics targeting several important human pathogens.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinsk bioteknologi -- Medicinsk bioteknologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Medical Biotechnology -- Medical Biotechnology (hsv//eng)
- NATURVETENSKAP -- Kemi -- Organisk kemi (hsv//swe)
- NATURAL SCIENCES -- Chemical Sciences -- Organic Chemistry (hsv//eng)
Nyckelord
- Thioredoxin reductase
- Redox biology
- Drug target
- Antibiotic resistance
- Staphylococcus aureus
- Mycobacterium tuberculosis
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas